Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

GuruFocus.com11-13

Total Revenue: $85 million for Q3 2024. Product Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023. Cost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023. R&D and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483028916?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4D80Lm0GEOItXKqpHDX6yg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e37d4e38e7850baaec70fee54fa44c04","is_english":true,"pubTime":"2024-11-13 15:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483028916","market":"us","top_or_hot":-1,"title":"Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $85 million for Q3 2024.\nProduct Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023.\nCost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023.\nR&D and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-inc-nvax-q3-2024-070809271.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-inc-nvax-q3-2024-070809271.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $85 million for Q3 2024.\nProduct Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023.\nCost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023.\nR&D and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-inc-nvax-q3-2024-070809271.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://finance.yahoo.com/news/novavax-inc-nvax-q3-2024-070809271.html","article_id":"2483028916","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4D80Lm0GEOItXKqpHDX6yg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e37d4e38e7850baaec70fee54fa44c04"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483028916","pubTimestamp":1731481689,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Product Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023.Cost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023.R&D and SG&A Expenses: $158 million for Q3 2024, a 26% reduction from Q3 2023.Cash Position: Over $1 billion in cash and accounts receivables at the end of Q3 2024.Revised Full Year 2024 Revenue Guidance: $650 million to $700 million.Revised Full Year 2024 Product Sales Guidance: $175 million to $225 million.Licensing, Royalties, and Other Revenue Guidance: Increased to $475 million for full year 2024.Future Milestones: Up to $700 million in near-term COVID-19 and flu/COVID combination milestones under the Sanofi Agreement.GuruFocus has detected 4 Warning Signs with NVAX.Novavax Inc  has a strong cash position, ending the third quarter with over a billion in cash and accounts receivables.The clinical hold on Novavax Inc 's COVID-19 influenza combination and standalone influenza vaccine candidates has been removed by the FDA, allowing them ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax Inc(NVAX)2024年第三季度收益看涨期权亮点：战略合作伙伴关系和财务……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1,"SNY":0.9},"content_text":"Total Revenue: $85 million for Q3 2024.\nProduct Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023.\nCost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023.\nR&D and SG&A Expenses: $158 million for Q3 2024, a 26% reduction from Q3 2023.\nCash Position: Over $1 billion in cash and accounts receivables at the end of Q3 2024.\nRevised Full Year 2024 Revenue Guidance: $650 million to $700 million.\nRevised Full Year 2024 Product Sales Guidance: $175 million to $225 million.\nLicensing, Royalties, and Other Revenue Guidance: Increased to $475 million for full year 2024.\nFuture Milestones: Up to $700 million in near-term COVID-19 and flu/COVID combination milestones under the Sanofi Agreement.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with NVAX.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nNovavax Inc (NASDAQ:NVAX) has established a strategic partnership with Sanofi, which will lead to double-digit royalties from Sanofi's sales of the COVID-19 vaccine starting in 2025.\nThe company has made significant progress in reshaping itself into a leaner and more agile organization, with a 26% reduction in R&D and SG&A expenses compared to the previous year.\nNovavax Inc (NASDAQ:NVAX) has a strong cash position, ending the third quarter with over a billion in cash and accounts receivables.\nThe clinical hold on Novavax Inc (NASDAQ:NVAX)'s COVID-19 influenza combination and standalone influenza vaccine candidates has been removed by the FDA, allowing them to proceed with phase three trials.\nThe company is leveraging its proven technology platform to drive additional partnerships and deals, with a focus on its Matrix-M adjuvant and nanoparticle protein-based technology.\n\n Negative Points \n\nNovavax Inc (NASDAQ:NVAX)'s current market share of approximately 3% is trending below their full season expectations, leading to a revision of their full-year 2024 total revenue guidance.\nThe company faces challenges such as minimum purchase commitment contracts for mRNA vaccines and limited initial retail stocking of their vaccine.\nThere is uncertainty regarding the timing of the phase three trial start for their COVID-19 influenza combination vaccine due to recent clinical hold issues.\nNovavax Inc (NASDAQ:NVAX) has revised its full-year 2024 product sales guidance downward, primarily due to COVID-19 trends in the US market.\nThe company is actively exploring the sale of its Czech Republic manufacturing facility, indicating potential operational downsizing.\n\n Q & A Highlights \nQ: Can you provide clarity on the timing for the start of the phase three trial following the clinical hold removal on your KIC and flu program? Are there any additional safety requirements from the FDA? A: We received the news about the clinical hold being lifted on Friday and are currently working on study logistics. We aim to start the trial as soon as possible but are not ready to provide a specific start date. The FDA's feedback supports our assessment that the serious adverse event was not related to our vaccine, so no additional safety precautions are needed beyond standard oversight.\nQ: Regarding your commercial sales, can you provide more details on the stocking versus actual shots administered? Also, what is your working assumption on the net price per dose? A: The season started earlier than last year, and we are seeing a leveling off of shots in arms. Our current market share is about 3%, and we are seeing an increase in restocking quantities. The net price per dose is expected to be in the range of 50% to 75% of the gross price, which is around $140 per dose.\nQ: How do you see the partnership with Sanofi impacting your market share and pricing dynamics next year? A: The partnership with Sanofi is expected to significantly enhance our market presence due to their extensive marketing capabilities and deep penetration in the vaccine space. Having our COVID vaccine alongside their flu vaccines should increase demand, and we anticipate significant progress in the 2025-26 season.\nQ: What are your expectations for the phase three KIC trial timeline, and will the standalone flu portion support registration? A: We plan to start the trial soon, but we are not committing to a specific timeline yet. The phase three trial is designed to demonstrate noninferior immunogenicity for both the KIC and standalone flu vaccines, and it is intended to support licensure, with a follow-on clinical efficacy trial needed post-approval.\nQ: Can you provide insight into how gross margins may change going forward? A: For 2025 and beyond, our cost of goods sold will reflect providing supply to Sanofi on a cost-plus basis. This means the traditional commercial relevance of gross margin will not apply in the same way as it did in previous years.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483028916"}